EW News and Press, Edwards Lifesciences Corporation From 12/18/20

Health Canada has approved expanded use of Edwards Lifesciences' ([[EW]] -0.6%) SAPIEN 3 and SAPIEN 3 Ultra transcatheter heart valves for the transfemoral treatment of patients diagnosed with severe symptomatic aortic stenosis (narrowing) who are at low risk for open-heart surgery.The compan...

Edwards SAPIEN 3 TAVI Receives Expanded Approval In Canada Valve Indicated for All Patients Diagnosed with Severe Symptomatic Aortic Stenosis Canada NewsWire MISSISSAUGA, Ontario , Dec. 18, 2020 /CNW/ -- Edwards Lifesciences Corporation today announced that H...

Wedgewood Partners’ 13F portfolio value increased from $590M to $632M this quarter. David Rolfe added First Republic Bank and doubled Microsoft while dropping Nvidia. Their top five positions are at 39% of the overall portfolio. For further details see: Tracking D...

Glenview Capital Management’s 13F portfolio value decreased from $3.63B to $3.19B this quarter. The number of positions increased from 43 to 45. They increased Myriad Genetics, while decreasing Quest Diagnostics, DaVita, and United Rentals during the quarter. The top three ...

Fisher’s 13F portfolio value increased from $102.5B to $117.8B in Q3 2020. They increased NextEra Energy, UnitedHealth, 3M Company, and Thermo Fisher Scientific while decreasing Starbucks, Total SA, and Royal Dutch Shell during the quarter. Fisher has a number of small posi...

The vote count to decide the next U.S. commander-in-chief is ongoing but healthcare investors do not appear concerned about who will eventually prevail since most industries are up in lockstep with the broad market rally.Big Biopharma leaders: Eli Lilly ([[LLY]] +14.6%), AbbVie ([[ABBV]] +9.4...

Surmodics is in the early stages of an extended growth period in our view, with high conversion potential from their pipeline. The company has key differentiators within its medical devices and IVD segments, with potential to generate long-tailed returns in manufacturing and distribut...

Strong Q3 exit with +6.4% growth in TAVR therapy sales, in spite of pressures from COVID-19. Shareholders have enjoyed +70% gains since March, however, with high volatility to the downside, which needs to be priced into the valuation. The stock has bounced away from support 3 time...

Image source: The Motley Fool. Edwards Lifesciences Corp (NYSE: EW) Q3 2020 Earnings Call Oct 21, 2020 , 5:00 p.m. ET Operator Continue reading For further details see: Edwards Lifesciences Corp (EW) Q3 2020 Earnings Call Transcript

Edwards Lifesciences Corporation (EW) Q3 2020 Earnings Conference Call October 21, 2020 17:00 ET Company Participants Mark Wilterding - President, Investor Relations Mike Mussallem - Chairman and Chief Executive Officer Scott Ullem - Chief Financial Officer Conference Call Participants David ...